ROCK and nuclear factor-κB-dependent activation of cyclooxygenase-2 by Rho GTPases: Effects on tumor growth and therapeutic consequences

Molecular Biology of the Cell

Volumn 14, Issue 7, 2003, Pages 3041-3054

  Benitah, Salvador Aznar ^a   Valerón, Pilar F ^a,b   Lacal, Juan Carlos ^a  

^a CSIC   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 117083; CYCLOOXYGENASE 2; GUANOSINE TRIPHOSPHATASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN CDC42; PROTEIN ROCK; RAC1 PROTEIN; RHO FACTOR; STAT3 PROTEIN; SULINDAC; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR GROWTH;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CDC42 GTP-BINDING PROTEIN; CELLS, CULTURED; CYCLOOXYGENASE 2; DNA-BINDING PROTEINS; DOGS; GENE EXPRESSION; HT29 CELLS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MICE; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RAC1 GTP-BINDING PROTEIN; RHOA GTP-BINDING PROTEIN; STAT3 TRANSCRIPTION FACTOR; SULFONAMIDES; SULINDAC; TRANS-ACTIVATORS;

ANIMALIA;

EID: 0038446034     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E03-01-0016     Document Type: Article

References (52)

1. Aznar, S., and Lacal, J.C. (2001a). Rho signals to cell growth and apoptosis. Cancer Lett. 165, 1-10.
2. Aznar, S., and Lacal, J.C. (2001b). Searching new targets for anticancer drug design: the families of Ras and RhoGTPases and their effectors. Prog. Nucleic Acid Res. Mol. Biol. 67, 193-234.
3. Aznar, S., and Lacal, J.C. (2003). Rho GTPases in human carcinogenesis: a tale of excess. Rev. Oncol. (in press).
4. Aznar, S., Valeron, P.F., del Rincon, S.V., Perez, L.F., Perona, R., and Lacal, J.C. (2001). Simultaneous tyrosine and serine phosphorylation of stat3 transcription factor is involved in rho a GTPase oncogenic transformation. Mol. Biol. Cell 12, 3282-3294.
5. Bar-Sagi, D., and Hall, A. (2000). Ras and Rho GTPases: a family reunion. Cell 103, 227-238.
6. Boerner, J.M., Danielsen, A.J., McManus, M.J., and Maihle, N.J. (2000). Activation of Rho is required for ligand-independent oncogenic signaling by a mutant EGF receptor. J. Biol. Chem. 10, 3691-3695.
7. Cao, Y., and Prescott, S.M. (2002). Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell. Physiol. 190, 279-286.
8. Crofford, L.J., Tan, B., McCarthy, C.J., and Hla, T. (1997). Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum. 40, 226-236.
9. Chiariello, M., Marinissen, M.J., and Gutkind, S. (2001). Regulation of c-myc expression by PDGF through Rho GTPases. Nat. Cell Biol. 3, 580-586.
10. Danen, E.H., Sonneveld, P., Sonnenberg, A., and Ymamda, K.M. (2000). Dual stimulation of Ras/mitogen-activated protein kinase and RhoA by cell adhesion to fibronectin supports growth factor-stimulated cell cycle progression. J. Cell Biol. 151, 1413-1422.
11. del Peso, L., Hernandez-Alcoceba, R., Embade, N., Carnero, A., Esteve, P., Paje, C., and Lacal, J.C. (1997). Rho proteins induce metastatic properties in vivo. Oncogene 15, 3047-3057.
12. Diaz-Cazorla, M., Perez-Sala, D., Ros, J., Jimenez, W., Fresno, M., and Lamas, S. (1999). Regulation of cyclooxygenase-2 expression in human mesangial cells-transcriptional inhibition by IL-13. Eur. J. Biochem. 260, 268-274.
13. Dubois, R.N. (2001). New paradigms for cancer prevention. Carcinogenesis 22, 691-692.
14. Embade, N., Valeron, P.F., Aznar, S., Lopez-Collazo, E., and Lacal, J.C. (2000). Apoptosis induced by Rac GTPase correlates with induction of FasL and ceramides production. Mol. Biol. Cell 11, 4347-4358.
15. Faruqi, T.R., Gomez, D., Bustelo, X.R., Bar-Sagi, D., and Reich, N.C. (2001). Rac1 mediates Stat3 activation by autocrine IL-6. Proc. Natl. Acad. Sci. USA 98, 9014-9019.
16. Gupta, R.A., and Dubois, R.N. (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase 2. Nat. Rev. Cancer 1, 11-21.
17. Hahn, A., Barth, H., Kress, M., Mertens, P.R., and Goppelt-Struebe, M. (2002). Role of Rac and Cdc42 in lysophosphatidic acid-mediated cyclo-oxygenase-2 gene expression. Biochem. J. 362, 33-40.
18. Jones, M.K., Wang, H., Peskar, B.M., Levin, E., Itani, R.M., Sarfeh, I.J., and Tarnawski, A.S. (1999). Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5, 1418-1423.
19. Karin, M., Cao, Y., Greten, F.R., and Li, Z.W. (2002). NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2, 301-310.
20. Lim, J.W., Kim, H., and Kim, K.H. (2001). Nuclear factor κB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab. Investig. 81, 349-360.
21. Liu, C.H., Chang, S-H., Narko, K., Trifan, O.C., Wu, M-T., Smith, E., Haudenschild, C., Lane, T.F., and Hla, T. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276, 18563-18569.
22. Mack Strong, V.E., Mackrell, P.J., Concannon, E.M., Mestre, J.R., Smyth, G.P., Schaefer, P.A., Stapleton, P.P., and Daly, J.M. (2001). NS-398 treatment after trauma modifies NF-κB activation and improves survival. J. Surg. Res. 98, 40-46.
23. Muller, J.M., Metzger, E., Greschik, H., Bosserhoff, A.K., Mercep, L., Buettner, R., and Schule, R. (2002). The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J. 21, 736-748.
24. Muller, S.M., Okan, E., and Jones, P. (2000). Regulation of urokinase receptor transcription by Ras- and Rho-family GTPases. Biochem. Biophys. Res. Commun. 270, 892-898.
25. Murga, C., Zohar, M., Teramoto, H., and Gutkind, J.S. (2002). Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-κB. Oncogene 21, 207-216.
26. Nur-E-Kamal, M.S.A., Kamal, J.M., Qureshi, M.M., and Maruta, H. (1999). The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation. Oncogene 18, 7787-7793.
27. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8, 289-293.
28. Perona, R., Esteve, P., Jimenez, B., Ballestero, R.P., Ramon y Cajal, S., and Lacal, J.C. (1993). Tumorigenic activity of rho genes from Aplysia californica. Oncogene 8, 1285-1292.
29. Pruitt, K:, and Der, C.J. (2001). Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 17, 1-10.
30. Psichari, E., Balmain, A., Plows, D., Zoumpourlis, V., and Pintzas, A. (2002). High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling. J. Biol. Chem. 277, 29490-29495.
31. Qiu, R.G., Chen, J., Kirn, D., McCormick, F., and Symons, M. (1995b). An essential role for Rac in Ras transformation. Nature 37, 457-459.
32. Qiu, R.G., Chen, J., McCormick, F., and Symons, M. (1995a). A role for Rho in Ras transformation. Proc. Natl. Acad. Sci. USA 92, 11781-11785.
33. Ridley, A.J. (2001). Rho family proteins: coordinating cell responses. Trends Cell Biol. 11, 471-477.
34. Sachdev, P., Jiang, X.Y., Li, W., Miki, T., Nur-E-Kamal, M.S., Wang, L.H. (2001). Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation. J. Biol. Chem. 276, 26461-26471.
35. Sahai, E. and Marshall, C.J. (2002) Rho-GTPases and cancer. Rev. Cancer 2, 133-142.
36. Schmedtje, J.F., Ji, Y.S., Lui, W.L., DuBois, R.N., and Runge, M.S. (1997). Hypoxia induces cyclooxygenase-2 via NF-κB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 272, 601-608.
37. Schmitz, A.A.P., Govek, E-E., Bottner, B., and Van Aelst, L. (2002). Rho GTPases: signaling, migration, and invasion. Exp. Cell Res. 261, 1-12.
38. Shao, J., Sheng, H., Inoue, H., Morrow, J.D., and DuBois, R.N. (2000). Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. 275, 33951-33956.
39. Sheng, H., Shao, J., and Dubois, R.N. (2001a). K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res. 61, 2670-2675.
40. Sheng, H., Shao, J., Washington, M.K., and DuBois, R.N. (2001b). Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 276, 18075-18081.
41. Simon, A.R., Vikis, H.G., Stewart, S., Fanburg, B.L., Cochran, B.H., and Guan, K.L. (2000). Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 290, 144-147.
42. Slice, L.W., Bui, L., Mak, C., and Walsh, J.H. (2000). Differential regulation of COX-2 transcription by Ras- and Rho-family of GTPases. Biochem. Biophys. Res. Commun. 276, 406-410.
43. Slice, L.W., Walsh, J.H., and Rozengurt, E. (1999). Gα 13 stimulates Rho-dependent activation of the cyclooxygenase-2 promoter. J. Biol. Chem. 274, 27562-27566.
44. Sotiropoulos, A., Gineitis, D., Copeland, J., and Treisman, R. (1999). Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. Cell 98, 159-169.
45. Taylor, M.T., Lawson, K.R., Ignatenko, N.A., Marek, S.E., Stringer, D.E., Skovan, B.A., and Gerner, E.W. (2000). Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 60, 6607-6610.
46. Tegeder, I., Pfeilschifter, and Geisslinger, G. (2001). Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15, 2057-2072.
47. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and Dubois, R.N. (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705-716.
48. Van Aelst, L., and D'Souza-Schorey, C. (1997). Rho GTPases and signaling network. Genes Dev. 11, 2295-2322.
49. van Leeuwen, F.N., van der Kammen, R.A., Habets, G.G., and Collard, J.G. (1995). Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells. Oncogene 11, 2215-2221.
50. Welsh, C.F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M.A., and Assoian, R.K. (2001). Timing of Cyclin D1 expression within G1 phase is controlled by Rho. Nat. Cell Biol. 3, 950-957.
51. Whitehead, I.P., Lambert, Q.T., Glaven, J.A., Abe, K., Rossman, K.L., Mahon, G.M., Trzaskos, J.M., Kay, R., Campbell, S., and Der, C.J. (1999). Dependence of Dbl and Dbs transformation on MEK and NF-κB activation. Mol. Cell. Biol. 19, 7759-7770.
52. Yamamoto, Y., Yin, M.-J., Lin, K.-M., and Gaynor, R. (1999). Sulindac inhibits activation of the NF-κB pathway. J. Biol. Chem. 274, 27307-27314.